Skip to content

Liposomal Bupivacaine for Quadratus Lumborum versus Transversus Abdominis Plane Block After Cesarean Delivery: A Prospective, Randomized, Double-Blind Trial

Liposomal Bupivacaine for Quadratus Lumborum versus Transversus Abdominis Plane Block After Cesarean Delivery: A Prospective, Randomized, Double-Blind Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129969
Enrollment
Unknown
Registered
2026-08-12
Start date
2026-08-19
Completion date
Unknown
Last updated
2026-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-cesarean analgesia

Interventions

Transversus abdominis plane block group:Transversus abdominis plane block with liposomal bupivacaine
Quadratus lumborum block group:Quadratus lumborum block with liposomal bupivacaine

Sponsors

The Third Xiangya Hospital Central South University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1.Scheduled to undergo elective cesarean delivery under single-shot spinal anesthesia; 2.Normal singleton pregnancy at =37 weeks of gestation; 3.Aged >18 and <55 years; 4.American Society of Anesthesiologists (ASA) physical status I or II; 5.Able to tolerate standard spinal anesthesia.

Exclusion criteria

Exclusion criteria: 1.Contraindications to neuraxial or regional anesthesia; 2.Allergy or intolerance to any study medication, such as sufentanil, ropivacaine, liposomal bupivacaine, or nonsteroidal anti-inflammatory drugs; 3.Body mass index (BMI) >40 kg/m²; 4.Body weight <40 kg in early pregnancy, based on the weight recorded at the 12-week antenatal visit, to exclude malnutrition or metabolic abnormalities; 5.Preeclampsia; 6.A history of chronic pain or regular opioid use; 7.Inability to understand the rating scales or cooperate with study assessments; 8.Conversion from neuraxial anesthesia to general anesthesia.

Design outcomes

Primary

MeasureTime frame
Cumulative PCA sufentanil consumption at 24 h after surgery;

Secondary

MeasureTime frame
Time to first postoperative flatus;Postoperative pain scores at rest, during movement, and during uterine contractions;Postoperative quality of recovery score;Cumulative postoperative consumption of nonsteroidal anti-inflammatory drugs;Incidence of postoperative adverse events;Incidence of postoperative nausea and vomiting;Time to first postoperative ambulation;Cumulative PCA sufentanil consumption at 48 h after surgery;

Countries

China

Contacts

Public ContactMinghua Chen

The Third Xiangya Hospital Central South University

7633013@QQ.com+86 731 8861 8938

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 19, 2026